Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer

American Journal of Surgery

Volumn 174, Issue 5, 1997, Pages 518-522

  Wanebo, Harold J ^a   Chougule, Prakash ^a   Akerley III, Wallace L ^a   Koness, R James ^a   McRae, Robert ^a   Nigri, Peter ^a   Leone, Louis ^a   Ready, Neal ^a   Safran, Howard ^a   Webber, Banice ^a   Cole, Bernard ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 0030657489     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00167-0     Document Type: Article

References (34)

1. Taylor SG, Applebaum E, Showel JL, et al. A randomized trial of adjuvant chemotherapy in head and neck cancer. J Clin Oncol. 1985;3:672-679.
2. Forastiere AA, Perry DJ, Wolf GT. Cisplatin and mitoguazone: an induction chemotherapy regimen in advanced head and neck cancer. Cancer. 1988;62:2304-2308.
3. Spaulding MB, Kahn A, Sundquist N, Lore JM. Preoperative chemotherapy for hypopharyngeal carcinoma. Laryngoscope. 1983; 93:346-349.
4. Roenne M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5FU infusion and cisplatin. Cancer. 1985;55:1123-1128.
5. Jacobs JR, Fu KF, Lowry LD, et al. Induction chemotherapy in advanced head and neck cancer. A radiation therapy oncology study. Arch Otolaryngol Head Neck Surg. 1987;113:193-197.
6. Johnson JT, Myers EN, Schramm VL, et al. Adjuvant chemotherapy for high-risk squamous cell carcinoma of the head and neck. J Clin Oncol. 1987;5:456-458.
7. Yokes EE, Panje WR, Mick R, et al. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990;66:206-213.
8. Merlano M, Grimaldi A, Benasso M, et al. Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. Am J Clin Oncol. 1988;11:538-542.
9. Mohit-Tabatabai MA, Rush BF, Hill GJ, et al. Multimodality preoperative treatment for advanced cancer of the head and neck. Am J Surg. 1984:148:521-524.
10. Rentschier RE, Wilbur DW, Petti GH, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas. A prospective, randomized study. J Clin Oncol. 1987;5:2 78-285.
11. Lerner HJ. Concomitant hydroxyurea and irradiation: clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania Hospital. Am J Surg. 1977;134:505-509.
12. Panis X, Nguyen T, Froissart D, Demauge L. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1984;6:1845-1849.
13. Lee DJ, Pajak TF, Stet J, et al. A phase I/II study of the hypoxic cell sensitizer misonidazole as adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys. 1989;16:465-470.
14. Slotman GJ, Cummings FJ, Glicksman AS, et al. Preoperative simultaneously administered cis-platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck. Head Neck Surg. 1987:8:159-164.
15. Glicksman AS, Slotman G, Doolittle C, et al. Concurrent cisplatinum with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994;30:1043-1050.
16. Crissman JD. Pajak TF, Zarbo RJ, et al. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck: an RTOG study of 114 advanced stage tumors. Cancer. 1987;59:1391-1397.
17. Taylor SG IV, Murphy AK, Caldarelli DD, et al. Combined simultaneous cisplatin/fluorouracil chemotherapy, and split course radiation in head and neck cancer. J Clin Oncol. 1989;7:846-856.
18. Adelstein DJ, Sharan VM, Earle AS, et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer. 1990;65:1685-1691.
19. Douple EB, Eaton WL, Tulloh ME. Skin radiosensitization studies using combined cis-dichlorodiammineplatinum (II) and radiation. Int J Radiat Oncol Biol Phys. 1979;5:1383-1385.
20. Haselow RE, Adams GL, Oken MM, et al. Cisplatinum (DDP) with radiation therapy (RT) for locally unresectable head and neck cancer. Proc Am Soc Gun Oncol. 1983;2:169.
21. Wanebo HJ, Glicksman AS, Landman C, et al. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. Am J Surg. 1995;170:512-516.
22. Geard CR, Jones JM, Schiff PB. Taxol and radiation, J Natl Cancer Inst. 1993;15:89-94.
23. Tischler R, Schiff P, Geard C, Hall EJ, Taxol: a novel radiation sensitizet. Int J Radiat Oncol Biol Phys. 1992;22:613-617.
24. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994:86:441-446.
25. Chov H, Akerley W, Safran H, et al. Phase 1 trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol. 1994:12:2682-2686.
26. Yokes EE, Haraf DJ, Stenseon L, et al. The role of paclitaxel in the treatment of head and neck cancer. Sem Oncol. 1995;22: 8-12.
27. Creaven P, Raghhavan D, Pendyala L, et al. Phase I study of paclitaxel and carboplatin: implications for trials in head and neck. Sem Oncol. 1995;22:13-16.
28. Aisner J, Belani CP, Kearns C, et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced squamous non-small cell lung cancer. Sem Oncol. 1995:22:17-21.
29. Forastiere AA, Flood W A, Kohn W, et al. Phase I study of paclitaxel administered 96 hours and cisplatin in patients with locally advanced squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 1996;15:884. Abstract.
30. Flood W A, Lee DJ, Trotti R, et al. A phase I study of weekly paclitaxel and cisplatin concurrenr with postoperative radiation therapy for treatment of high-risk patients with squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol. 1996;15:885. Abstract.
31. Couteau C, Leyraz S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol. 1996; 15:889. Abstract.
32. Kambhu S, Clamon G, Doornbos F, et al. Phase II trial of Taxol and cisplatin in advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996;15:917. Abstract.
33. Steinberg L, Hassen M, Hoppel C, et al. A phase I study of tadiotherapy (RT) and simultaneous paclitaxel (Pac) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 1996;15:913. Abstract.
34. Hoffmann W, Schmidberoer H, Hess CF, et al. Phase 1 study with weekly paclitaxel and simultaneous radiation in locally advanced inoperable squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996;15:914. Abstract.